Fatty liver disease as a risk factor for impaired hemostasis in patients with COVID-19
https://doi.org/10.25789/YMJ.2025.89.25
Abstract
The effect of fatty liver disease (FLD) on hemostasis disorders in COVID-19 was studied. Hemostasis disorders were detected in 30% of COVID-19 deaths. FLD was more common (19%) in COVID-19 deaths with hemostasis disorders than in COVID-19 deaths without hemostasis disorders (12%), p = 0.019. Thus, the study results showed statistical significance of hemostasis pathology in the COVID-19 mortality structure.
About the Authors
O. V. Tirikova
ФГБОУ ВО «Иркутский государственный медицинский университет»
Russian Federation
Russian Federation
D. V. Sudyarova
ФГБОУ ВО «Иркутский государственный медицинский университет»
Russian Federation
Russian Federation
N. B. Elmurodova
ФГБОУ ВО «Иркутский государственный медицинский университет»
Russian Federation
Russian Federation
References
1. Ivashkin V.T., Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for Liver Research and the Russian Gastroenterological Association // Russian Journal of Gastroenterology. Hepatol. Coloproctol. 2016. Vol. 26. No. 2. P. 24 – 42.
2. Tirikova O.V., Kozlova N.M., Eliseev et al. Endothelial dysfunction in patients with non-alcoholic fatty liver disease. Experimental and clinical gastroenterology. 2022;203(7): 45–53. DOI: 10.31146/1682-8658-ecg-203-7-45-53
3. Tirikova O.V., Dissertation for the degree of Candidate of Medical Sciences: Clinical and morphological aspects of non-alcoholic fatty liver disease and its association with cardiovascular pathology. Diss. … cand. med. sciences p.78
4. A new definition of metabolically associated fatty liver disease: a consensus statement by international experts / M. Eslam [et al.] // Journal of Hepatology. 2020. Volume 73. Number 1. Р. 202-209.
5. Brunt E.M. Pathology of fatty liver disease // Modern Pathology. 2007. Vol. 20. N. 40. Р. 48.
6. Carme Font. Thrombosis, cancer, and COVID-19 / Norman Brito-Dellan., Nikolaos Tsoukalas // Support Care Cancer. 2022; 30(10): 8491–8500.
7. COVID-19 and its control: mechanical and clinical studies / T. Marzha, G.J. Webb, A.S. Barrett [et al.] // The State Environmental Protection Inspectorate. May 2021;18(5):348-364. doi: 10.1038/s41575-021-00426-4.
8. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin – induced cardiovascular disorders / Wattanpitayakul S.K. [et al.] // FASEB J. 2000;14(2):271–278. doi: 10.1096/fasebj.14.2.271.
9. Increased activity of blood coagulation factors VIII, IX, XI and XII in non-alcoholic fatty liver disease / A. Kotronen, L. Yutsi-Korhonen, K. Sevastyanova [et al.] // Liver, February 2011;31(2):176-83. doi: 10.1111/j.1478-3231.2010.02375. x.
10. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter / Stefan Kiriak, Carol Stanciu [et al.] // Gastroenterol Hepatol. 2021; 2021: 6696857.
11. Nonalcoholic fatty liver disease 2020: the state of the disease / Thomas G. Cotter., Mary Rinella // Gastroenterology. 2020.158.7. Р. 1851-1864.
12. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways / Ding YQ, He L, Zhang QL [et al.] // J Pathol. 2004;203(2):622-630.
13. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease // Journal of Hepatology. 2008. Vol. 49. N 4. P. 608 612. DOI: 10.1016/j.jhep.2008.06.018.
14. Pathophysiology of COVID-19: the critical role of hemostasis / de Andrade, S.A., de Souza, D.A., Torres, A.L. [et al.] // Microbiol infects the anterior cell. 2022, June 3;12:896972. doi: 10.3389/fcimb.2022.896972.
15. Thrombosis in COVID-19 / Hanff TC. et al. // Am J Hematol. 2020; 95 :1578–1589.
16. Тohandas S, Vairappan B. Severe acute respiratory syndrome coronavirus-2 infection and the gut–liver axis. J Dig Dis. 2020; 21:687–695.
Review
For citations:
Tirikova O.V., Sudyarova D.V., Elmurodova N.B. Fatty liver disease as a risk factor for impaired hemostasis in patients with COVID-19. Yakut Medical Journal. 2025;(1):111-114. https://doi.org/10.25789/YMJ.2025.89.25
Views:
92
Email this article 